Ipsen SA, of Paris, disclosed top-line results for two double-blind phase III studies of Dysport (abobotulinumtoxin A) in pediatric lower limb (PLL) spasticity in children with cerebral palsy and in adult lower limb (ALL) spasticity in patients who had experienced a stroke or traumatic brain injury.